Mitsubishi Tanabe Pharma Corporation

Iwao Takamuro

Kosuke Yasuda

Hiroshi Miyazaki

Tetsuya Yanagida

Osamu Sakurai

Yutaka Hisada

Junko Tsubakimoto

Junko Okabe

Hiroshi Sugama

Yasunori Tsuboi

Hiroyuki Taniguchi

Kazutoshi Sugawara

Osamu Sakural

Yataka Hisada

Yasuo Sekine

Kouji Nogi

An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof. 

Arylalkylamine compound and process for preparing the same

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.  The symbols in the formula represent the following meanings:

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. 

A hydrazone derivative of formula [I]: wherein Ring A is aryl or heteroaryl, Ring T is heteroaryl or heterocycle, Rand Rare independently hydrogen atom, halogen atom, cycloalkylsulfonyl, etc., Rand Rcombine each other together with the adjacent nitrogen atom to form substituted or unsubstituted heterocycle, Ris hydrogen atom, halogen atom, cyano, nitro, tetrazolyl, etc., and Ris hydrogen atom, etc.;or a pharmaceutically acceptable salt thereof is useful as a glucokinase activation agent.

Hydrazone derivative

The present invention provides a novel pyrazolopyrimidine compound of the formula [I]: wherein R' is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, Ris (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: &#x2014;CO&#x2014;, &#x2014;CH2-, &#x2014;SO2- or a group of the formula [II]: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable sait thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same 

Pyrazolopyrimidine compound and a process for preparing the same

Growing community of inventors

Osaka, Japan

Iwao Takamuro